EUCTR2013-002416-27-DK进行中（未招募）1 期
Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality. - The INFECIR-2 Albumin Prevention Study
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 512
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male and Female patients with age >/= 18 years.
- •- Diagnosis of liver cirrhosis established by histology or by the combination of clinical, analytical and ultrasonographic data.
- •- Diagnosis of urinary infection, pneumonia, spontaneous or secondary bacteremia, skin/soft tissue infection, acute cholangitis or suspected bacterial infection at hospital admission or during hospitalisation. Diagnostic criteria at inclusion will be the following:
- •(a) urinary infections signs of systemic imflammation and more than 10 leukocytes per high-power field in urine or a positive reagent; (b) pneumonia - signs of infection and presence of new infiltrates on chest x-ray; (c) skin/soft tissue infection - signs of infection and physical exam findings of swelling, erythema, heat and tenderness in the skin; (d) acute cholangitis - signs of infection and cholestasis, compatible symptoms (right upper quadrant pain and jaundice) and radiological data of biliary obstruction; (e) Spontaneous bacteremia: positive blood cultures and no cause of bacteremia; (f) Secondary bacteremia: positive blood and catheter cultures or bacteremia within 24h after invasive procedure; (g) Suspected bacterial infection: signs of systemic inflammation but no identifiable origin of this infection (polymorphonuclear cells in ascitic and pleural fluid < 250/mm3, normal urine sediment and chest X-ray). Patients with uncomplicated urinary infections or suspected bacterial infections will require the presence of signs of systemic inflammation: at least 1 diagnostic criterion of systemic inflammatory response syndrome (SIRS) and high serum CRP levels =1 mg/dl (10mg/L). This criterion will not be required for the rest of infections.
- •- Presence of renal and/or liver dysfunction (serum creatinine =1.2 mg/dl, serum bilirubin =4 mg/dl or serum sodium = 130 mEq/l). Patients with pneumonia or documented bacteremia (positive blood cultures) will require the presence of at least 1 of these analytical criteria to be included in the study. Two or more criteria will be required in patients with urinary infection, skin/soft tissue infection, acute cholangitis or suspected bacterial infection.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 362
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •- > 72h after the diagnosis of infection.
- •- Pre-menopausal women (last menstruation = 12 months prior to enrolment) who are nursing or pregnant or are of child bearing potential and are not practicing an acceptable method of birth control. The methods considered as acceptable are: intrauterine devices, double barrier method (condom or diaphragm with spermicide), hormonal methods (oral contraceptives, contraceptive patch, long acting injectable contraceptive) and tubal ligation.
- •- Acute or subacute liver failure without underlying cirrhosis.
- •- Septic shock (mean arterial pressure below 60 mmHg during more than 1 hour despite adequate fluid resuscitation and need of vasopressor drugs).
- •- Severe acute respiratory distress syndrome [PaO2/Fi02 =100 or a pulse oximetric saturation (SpO2) to FiO2 ratio =89].
- •- Active or recent variceal bleeding (unless controlled for >48h).
- •- Ongoing Type-1 HRS (IAC criteria: serum creatinine = 2.5 mg/dl).
- •- Type-3 ACLF.
- •- Hemodialysis or other type of renal replacement therapy.
- •- Evidence of current malignancy (except for hepatocellular carcinoma within Milan criteria or non-melanocytic skin cancer),
- •- Previously known moderate or severe chronic heart failure (NYHA class II, III or IV).
- •- Previously known severe chronic pulmonary disease (GOLD IV).
- •- Previously known severe psychiatric disorders that prevent the patient from giving informed consent and from making autonomous decisions.
- •- Previous Liver transplantation
- •- Previously known HIV infection (except for patients under antiretroviral therapy with undetectable viral load, CD4 levels >200/mm3 and no previous history of opportunistic infections diagnostic of AIDS).
- •- Contraindications to albumin (allergy, signs of pulmonary edema)
- •- Albumin administration of >/=80g of albumin in the last 2 days
- •- Refusal to participate.
- •- Patients who cannot provide prior informed consent and when there is documented evidence that the patient has no legal surrogate decision maker and it appears unlikely that the patient will regain consciousness or sufficient ability to provide delayed informed consent.
- •- Physician and team not committed to intensive care if needed.
- •- Usage of any investigational drug within 90 days prior to randomization or the planned use of an investigational drug during the course of the current study.
- •All patients meeting the inclusion criteria will be entered on a screening log. If the patient is not enrolled, the screening log will include information explaining why enrollment did not occur.
研究者
相似试验
进行中（未招募）
不适用
Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality.EUCTR2013-002416-27-NLFundacio Clinic per a la recerca biomedica512
进行中（未招募）
1 期
Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality.EUCTR2013-002416-27-BEFundacio Clinic per a la recerca biomedica512
进行中（未招募）
1 期
Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality.Male and female cirrhotic patients with advanced cirrhosis (serum creatinine = 1.2 mg/dl, serum sodium = 130 mEq/l and/or serum bilirubin =4 mg/dl), and diagnosis of urinary infection, pneumonia, spontaneous or secondary bacteremia, skin/soft tissue infection, acute cholangitis or suspected bacterial infection at hospital admission or during hospitalization.MedDRA version: 18.1Level: LLTClassification code 10008954Term: Chronic liver disease and cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 18.1Level: LLTClassification code 10024667Term: Liver cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 18.1Level: PTClassification code 10019641Term: Hepatic cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 18.1Level: LLTClassification code 10064704Term: Decompensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 18.1Level: LLTClassification code 10009213Term: Cirrhosis of liverSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 18.1Level: LLTClassification code 10009211Term: Cirrhosis liverSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2013-002416-27-DEFundacio Clinic per a la Recerca Biomedica512
进行中（未招募）
1 期
Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality.EUCTR2013-002416-27-GBFundacio Clinic per a la recerca biomedica512
进行中（未招募）
不适用
Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mortality.EUCTR2013-002416-27-NOFundacio Clinic per a la recerca biomedica512